Northvale, New Jersey, Thursday, November 30, 2006:Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (AMEX: ELI), has been selected to present in Bank of Montreal’s 2006 Focus on Healthcare Conference. Bernard Berk, Elite’s Chairman and Chief Executive Officer will discuss the Company’s two lead opioid products: ELI-216, the Company’s abuse-deterrent oxycodone hydrochloride product using ART, and ELI-154, its once-daily oxycodone hydrochloride product along with its pipeline of other oral controlled-release products addressing niche markets.
The conference will be held at the Millennium Broadway Hotel at 145 West 44th Street, in New York City and the Company will be presenting on Thursday, December 7, at 9:15 a.m. EST. A live webcast of the presentation will be available on the Company website www.elitepharma.com and archived for 90 days. Additional information regarding the conference can be found at http://www.bmocm.com/conferences/healthcare2006/default.aspx.
About Elite Pharmaceuticals Elite Pharmaceuticals is a specialty pharmaceutical company principally engaged in the development and manufacturing of oral controlled-release products. The Company's strategy includes developing generic versions of controlled release drug products with high barriers to entry and assisting partner companies in the life cycle management of products to improve off-patent drug products. Elite's technology is applicable to develop delayed, sustained or targeted release capsules or tablets. Elite has one product currently being sold commercially and a pipeline of eight drug products under development in the therapeutic areas that include pain management, allergy, cardiovascular and infection. The addressable market for Elite's current pipeline of products exceeds $6 billion. Elite also has a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
For Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations Phone: 518-398-6222 E-Mail: dwill@willstar.net
Website: www.elitepharma.com
This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of the Company, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. The Company undertakes no obligation to update any forward-looking statements. |